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ABSTRACT
Objective: To use the Visual Object and Space Perception Battery (VOSP) to distinguish Alzheimer
disease (AD) from non-AD pathology in corticobasal syndrome (CBS).
Methods: This clinicopathologic study assessed 36 patients with CBS on the VOSP. All were
autopsied. The primary dependent variable was a binary pathologic outcome: patients with
CBS who had primary pathologic diagnosis of AD (CBS-AD, n5 10) vs patients with CBS without
primary pathologic diagnosis of AD (CBS-nonAD, n 5 26). We also determined sensitivity and
specificity of individual VOSP subtests.
Results: Patients with CBS-AD had younger onset (54.5 vs 63.6 years, p 5 0.001) and lower
memory scores on the Mattis Dementia Rating Scale–2 (16 vs 22 points, p 5 0.003). Failure on
the VOSP subtests Incomplete Letters (odds ratio [OR] 11.5, p5 0.006), Position Discrimination
(OR 10.86, p 5 0.008), Number Location (OR 12.27, p 5 0.026), and Cube Analysis (OR 45.71
p 5 0.0001) had significantly greater odds of CBS-AD than CBS-nonAD. These associations
remained when adjusting for total Mattis Dementia Rating score, disease laterality, education,
age, and sex. Receiver operating characteristic curves demonstrated significant accuracy for
Incomplete Letters and all VOSP spatial subtests, with Cube Analysis performing best (area under
the curve 0.91, p 5 0.0004).
Conclusions: In patients with CBS, failure on specific VOSP subtests is associated with greater
odds of having underlying AD. There may be preferential involvement of the dorsal stream in
CBS-AD.
Classification of evidence: This study provides Class II evidence that some subtests of the VOSP
accurately distinguish patients with CBS-AD from those without AD pathology (e.g., Cube Anal-
ysis sensitivity 100%, specificity 77%). Neurology® 2014;83:510–519
GLOSSARY
AD5Alzheimer disease;CBD5 corticobasal degeneration;CBS5 corticobasal syndrome;DRS-25Mattis Dementia Rating
Scale-2; FTLD-TDP 5 frontotemporal lobar degeneration with TDP43-positive inclusions; OR 5 odds ratio; PD 5 Parkinson
disease; PSP 5 progressive supranuclear palsy; ROC 5 receiver operating characteristic; VOSP 5 Visual Object and Space
Perception Battery; WMS-III 5 Wechsler Memory Scale III.
The corticobasal syndrome (CBS) is characterized by significant cognitive impairment.1–3 Cor-
ticobasal degeneration (CBD), the classic pathologic entity, is often not seen on autopsy in
patients with CBS. Frequently, patients with CBS are found, postmortem, to have pathology of
Alzheimer disease (CBS-AD), progressive supranuclear palsy (CBS-PSP), or other non-CBD
pathologies.3–10
Of the various pathologic substrates of CBS, AD is common, accounting for more than 20%
of cases.3,5,9,10 Antemortem diagnosis of CBS-AD is important, because patients may benefit
from cholinesterase inhibitors or future AD-targeted treatments. Furthermore, understanding
atypical presentations of AD may reveal aspects of AD pathophysiology, leading to novel ther-
apies. Research on aspects of CBS-AD has not been hypothesis-driven, but a review has iden-
tified shared CBS-AD features between studies, including visuospatial deficits.11
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Impairment of visual perception in CBS has
been measured using the Visual Object and Spa-
tial Perception Battery (VOSP), a test that is
divided into object and space processing, associ-
ated with temporal “ventral” and parietal “dorsal”
stream pathways, respectively. Neuroimaging
research has revealed that atrophy in CBS-AD
extends posteriorly, to regions in the parietotem-
poral lobe.4,5,12–14 Given the preferential involve-
ment of the parietal lobe in CBS-AD, specific
impairment in dorsal stream visual perception
would be expected.
We hypothesized that visual perception test-
ing would distinguish CBS-AD from CBS pa-
tients without a primary pathologic diagnosis
of AD (CBS-nonAD). Our secondary hypothe-
sis was that failure on VOSP subtests of spatial
perception would be associated with greater risk
of CBS-AD when compared with CBS-nonAD.
METHODS Subjects and clinical testing. Subjects were
derived from a cohort of 98 patients with CBS who were enrolled
at the National Institute of Neurological Disorders and Stroke
from 2001 to 2009. Patients were recruited from across the coun-
try via advertisement. There were numerous referral centers and
some patients were referred by individual neurologists. After
referral, diagnosis of CBS was confirmed by a behavioral neurol-
ogist with experience in movement disorders (E.M.W.) and a
neuropsychologist (J.G.) via consensus following a week’s evalu-
ation. Patient evaluations included brain imaging, genetic testing,
and core clinical neuropsychological and neurologic workups.
The case definition for CBS was based on published criteria15
and consisted of progressive, predominantly lateralized ideomotor
apraxia and/or non–DOPA-responsive extrapyramidal motor
dysfunction (limb dystonia or rigidity) with cortical sensory loss
(astereognosis, agraphesthesia), and no explanatory focal pathol-
ogy on MRI (supplemental data on the Neurology® Web site at
Neurology.org). Every patient was extensively discussed, and
observations of the signs were noted over the week for their
consistency and reliability. Inclusion criteria consisted of our
confirmation of CBS. Patients were excluded if they lacked a
participating caregiver, if they were diagnosed with another
neurodegenerative condition, or if their behavior precluded
neuropsychological testing. Surviving patients were not followed
after 2009.
Laterality of the affected brain region was defined as contralat-
eral to the initial motor deficit. Dementia severity was assessed
using the Mattis Dementia Rating Scale–2 (DRS-2). Praxis was
assessed using the composite standardized score from the Test of
Oral and Limb Apraxia. Visual memory was examined using the
visual memory subscales ofWechsler Memory Scale III (WMS-III).
Neuropsychiatric components were quantified using the Neuropsy-
chiatry Inventory. Category and letter fluency were also assessed.
Symptom duration was defined as the time of symptom onset
(historical report) until evaluation. Disease duration was defined
as time of symptom onset until death.
Visual Object and Space Perception Battery. Visual percep-
tion was the primary predictor and was evaluated using the
VOSP. This test has shown construct validity in assessing ventral
and dorsal streams of visual processing.16 Subjects are first
screened for requisite acuity with cards containing a degraded “X”
and must indicate whether or not the X is present. See figure 1 for
test description.
Standard protocol approvals, registrations, and patient
consents. The patients gave assent for the study. The study and
consent procedure were approved by the National Institute of
Neurological Disorders and Stroke review board.
Neuropathologic diagnosis. The 39 patients who came to
autopsy comprised the cohort. Primary diagnosis of AD was estab-
lished usingNational Institute on Aging–Reagan criteria, while other
diagnoses were made using published criteria.17–21 To belong to the
CBS-AD group, cases had to have a primary diagnosis of high-
likelihood AD. Those subjects with alternate primary diagnoses
(with or without secondary diagnoses of intermediate- or low-
probability AD) were categorized as CBS-nonAD.
Genetics. Genetic testing for APOE was performed on a subset
of subjects.
Statistical analysis. The cohort was divided into 2 subgroups
for primary analysis: CBS patients with primary underlying path-
ologic diagnosis of AD (CBS-AD) vs CBS patients without pri-
mary underlying pathologic diagnosis of AD (CBS-nonAD). A
secondary analysis was performed on 3 subgroups, consisting of
CBS-AD, CBS-CBD, and CBS-other (CBS patients without a
primary pathologic diagnosis of either AD or CBD). For
bivariate analysis, continuous outcome variables were assessed
using Kruskal-Wallis or Mann-Whitney U tests, and categorical
outcome variables were assessed with x2 or Fisher exact test.
Logistic regression was performed for all multivariable analyses.
VOSP subtest failure was selected as a categorical binary predictor
variable. Individual VOSP subtests were assessed one at a time in
isolation. Each VOSP subtest was then separately combined with
one covariate at a time (i.e., multivariable analysis included
separate logistic regression models for each covariate of
interest). Covariates were selected on the basis of biologically
being potential confounders and included Mattis DRS-2 score,
age at visit, sex, education, and symptom laterality.
Receiver operating characteristic (ROC) curves were con-
structed, and their accuracy was determined. Using the VOSP
as a clinical test, 2 diagnostic parameters were calculated: (1) sen-
sitivity for test cutoff value—the percentage of pathologically
confirmed CBS-AD cases that would be clinically diagnosed as
having CBS-AD based on a listed VOSP subtest score; and (2)
specificity for test cutoff value—the percentage of pathologically
confirmed CBS-nonAD cases that would be clinically diagnosed
as not having CBS-AD, based on a listed VOSP subtest score. We
chose cutoff values that yielded the largest combined sensitivity
and specificity. Predictive values would depend on the prevalence
of CBS-AD in our CBS cohort, while sensitivity and specificity
would not. Because this is a pathologic study including only those
who came to death during the study period (39/98), the preva-
lence of various pathologies may not be representative of the
population; thus, predictive values were not calculated.
Statistical analysis was performed using statistical software IBM
Statistical Package for the Social Sciences (SPSS 19.0; IBM Corp.,
Armonk, NY). Level of statistical significance was set to a , 0.05.
Correction for multiple comparisons was not utilized, because
impairment on the VOSP in general (and on spatial subtests in
particular) was identified a priori as a predictor for CBS-AD.
RESULTS Primary pathologic findings and grouping
by pathology. The most frequently encountered
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pathology was CBD, which was present in 15 of 39 sub-
jects (39%). AD was the second most common pathol-
ogy (12/39, 31%), followed by PSP (6/39, 15%). The
remaining pathologic diagnoses consisted of frontotem-
poral lobar degeneration (FTLD) (3/39; all FTLD-
TDP), multisystem atrophy (2/39), and Parkinson
disease (PD) (1/39). The VOSP was available for 36
of 39 subjects; excluded subjects consisted of 2
subjects with CBS-AD and 1 subject with CBS-CBD.
Secondary pathologic diagnoses. Of the 12 CBS-AD
cases, secondary pathologic diagnoses included
cerebrovascular disease (7), neocortical Lewy body
disease (3), and amygdala a-synucleinopathy (2).
The remaining cases belonged to the CBS-nonAD
group: of the 15 CBS-CBD cases, secondary
pathologic diagnoses included cerebrovascular disease
(4), low-probability AD (Braak stage II), and PD (2).
Secondary pathologic diagnoses for the 12 CBS-other
Figure 1 Visual Object and Space Perception Battery
Visual Object and Space Perception Battery (VOSP). Copyright © (1991) by Elizabeth K Warrington & Merle James,
published by Pearson Education Ltd. Reproduced with permission. All rights reserved. *Cutoff values for failure based on
the VOSP manual and established by published norms.
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Table 1 Subject demographics, clinical symptoms and signs, and genetics
CBS-AD vs CBS-CBD vs CBS-other CBS-AD vs CBS-nonAD
CBS-AD (n 5 10) CBS-CBD (n 5 14) CBS-other (n 5 12) p Valuea CBS-AD (n 5 10) CBS-nonAD (n 5 26) p Valuea
Sex, % M 50, F 50 M 57, F 43 M 50, F 50 0.916 M 50, F 50 M 54, F 46 0.564
Age at symptom onset, y 54.50 (5.86) 63.00 (5.36) 64.33 (9.63) 0.004b,c 54.50 (5.86) 63.62 (7.50) 0.001b
Ethnicity, % 100 WNH 100 WNH 100 WNH NA 100 WNH 100 WNH NA
Education, y 15.40 (3.06) 14.00 (2.72) 14.83 (2.29) 0.584 15.40 (3.06) 14.38 (2.52) 0.411
Handedness, % R 100 R 93, L 7 R 92, L 8 0.507 R 100 R 92, L 8 0.516
Age at evaluation, y 58.60 (5.02) 67.93 (5.33) 68.92 (10.15) 0.002b,d 58.60 (5.02) 68.38 (7.77) 0.0005b
Symptom duration at evaluation, y 4.10 (2.07) 4.79 (1.88) 4.43 (2.50) 0.757 4.10 (2.07) 4.62 (2.15) 0.614
Time evaluation until death, y 2.69 (1.12) 2.46 (1.66) 2.30 (1.32) 0.727 2.69 (1.12) 2.39 (1.49) 0.454
Disease duration, y 6.90 (2.56) 7.29 (2.05) 6.83 (2.12) 0.982 6.90 (2.56) 7.08 (2.06) 0.988
Progression 5 symptom duration at evaluation/disease duration 0.58 (0.19) 0.66 (0.22) 0.62 (0.24) 0.619 0.58 (0.19) 0.64 (0.23) 0.413
Disease laterality, brain, % L 50, R 50 L 57, R 43 L 43, R 57 0.912 L 50, R 50 L 50, R 50 0.644
Mattis DRS-2 total (SD) 98.30 (28.59) 105.50 (26.02) 123.58 (15.61) 0.074 98.30 (28.59) 113.85 (23.32) 0.109
Mattis DRS-2 Attention (SD) 28.40 (7.41) 30.29 (6.80) 34.67 (2.74) 0.030b,e 28.40 (7.41) 32.31 (5.68) 0.053
Mattis DRS-2 Initiation (SD) 19.50 (10.81) 20.14 (11.89) 27.50 (10.01) 0.192 19.50 (10.81) 23.54 (11.47) 0.393
Mattis DRS-2 Construction (SD) 1.40 (1.84) 1.93 (2.40) 3.08 (2.23) 0.155 1.40 (1.84) 2.46 (2.35) 0.286
Mattis DRS-2 Conceptualization (SD) 33.10 (6.51) 32.43 (5.14) 35.75 (2.53) 0.177 33.10 (6.51) 33.96 (4.40) 0.903
Mattis DRS-2 Memory (SD) 16.00 (5.48) 20.71 (4.20) 22.58 (2.43) 0.009b,f 16.00 (5.48) 21.58 (3.56) 0.003b
Neurobehavior Rating Scale (SD) 48.40 (10.53) 44.50 (10.66) 44.17 (5.98) 0.395 48.40 (10.53) 44.35 (8.65) 0.189
Praxis, TOLA composite SS (SD) 99.50 (7.18) 94.86 (13.36) 101.83 (7.00) 0.378 99.50 (7.18) 98.08 (11.27) 0.958
Letter Fluency (SD) 17.50 (7.72) 13.64 (9.83) 22.78 (8.77) 0.028b,g 17.50 (7.72) 17.22 (10.29) 0.773
Category Fluency (SD) 20.50 (11.55) 20.14 (11.57) 25.22 (5.67) 0.447 20.50 (11.55) 22.13 (9.86) 0.499
WMS-III Visual, VI Index (SD) 80.50 (11.98) 83.93 (9.04) 88.75 (19.26) 0.790 80.50 (11.98) 86.15 (14.55) 0.520
WMS-III Visual, VD Index (SD) 80.40 (16.12) 87.29 (12.91) 95.92 (21.38) 0.304 80.40 (16.12) 91.27 (17.52) 0.155
Frequency/no. tested for 1 APOE e4 allele 4/8 5/14 1/11 0.165 4/8 6/25 0.164
Abbreviations: AD 5 Alzheimer disease; CBD 5 corticobasal degeneration; CBS 5 corticobasal syndrome; DRS-2 5Mattis Dementia Rating Scale–2; NA 5 not applicable; SS 5 standardized score; TOLA 5 Test of
Oral and Limb Apraxia; VD 5 visual delayed; VI 5 visual immediate; WMS-III 5 Wechsler Memory Scale III; WNH 5 white non-Hispanic.
Age (at symptom onset, at evaluation), education, symptom duration (at evaluation, from evaluation until death), total disease duration, and progression are reported as means (SD).
aKruskal-Wallis test used for continuous variables, x2 or Fisher exact test used for categorical variables.
bSignificant values.
c Post hoc Mann-Whitney U: CBS-AD vs CBS-CBD p 5 0.001; CBS-AD vs CBS-other p 5 0.012; CBS-CBD vs CBS-other 5 0.519.
dPost hoc Mann-Whitney U: CBS-AD vs CBS-CBD p 5 0.001; CBS-AD vs CBS-other p 5 0.008; CBS-CBD vs CBS-other p 5 0.589.
ePost hoc Mann-Whitney U: CBS-AD vs CBS-CBD p 5 0.411; CBS-AD vs CBS-other p 5 0.006; CBS-CBD vs CBS-other p 5 0.100.
f Post hoc Mann-Whitney U: CBS-AD vs CBS-CBD p 50.034; CBS-AD vs CBS-other p 5 0.002; CBS-CBD vs CBS-other p 5 0.390.
gPost hoc Mann-Whitney U: CBS-AD vs CBS-CBD p 5 0.150; CBS-AD vs CBS-other p 5 0.182; CBS-CBD vs CBS-other p 5 0.012.
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group included low- to intermediate-probability
AD (4 patients: 1 multiple system atrophy with
Braak stage III AD; 1 PD with Braak III AD; and
2 PSP with Braak stage II AD) and cerebrovascular
disease (2). In all groups, cerebrovascular disease
primarily consisted of atherosclerosis, arteriolosclerosis,
or isolated lacunar infarct.
Subject characteristics. In the primary analysis com-
paring CBS-AD vs CBS-nonAD, the subjects with
CBS-AD were significantly younger at symptom
onset and time of assessment. A secondary analysis
comparing CBS-AD, CBS-CBD, and CBS-other
revealed that the CBS-AD group was significantly
younger than both the CBS-CBD group and the
CBS-other group at symptom onset and time of
assessment (table 1). Clinical features of CBS-AD
vs CBS-nonAD can be found in table e-1.
Memory. The CBS-AD group showed impaired
Mattis DRS-2 Memory subscale scores compared with
CBS-nonAD and also compared with CBS-CBD and
with CBS-other. Secondary analysis also demonstrated
significantly lower Mattis DRS-2 Attention subscale
scores for CBS-AD vs CBS-other (see table 1).
Visual perception test failure on outcome CBS-AD vs
CBS-nonAD. The VOSP was available for only 36 of
39 patients because of incomplete records. Test failure
on the VOSP was used to determine an outcome of
CBS-AD (where test failure indicated a “test positive”
result). In bivariate analysis, failure on VOSP subtests
Incomplete Letters, Position Discrimination, Number
Location, and Cube Analysis was significantly
associated with greater odds of CBS-AD as compared
with CBS-nonAD (table 2). These associations remained
significant when the 3 patients with CBS-AD who had
Table 2 Visual perception (VOSP) vs global measure of dementia (Mattis DRS-2) as predictors of CBS-AD
compared with CBS-nonAD
Unadjusted OR
(95% CI)
Unadjusted
p valuea
Adjusted OR
(95% CI)
Adjusted
p valueb
VOSP subtest failure on outcome of
CBS-AD, with and without adjustment
for Mattis DRS-2 total score
Failed subtest used
Incomplete Letters 11.50 (2.01–65.91) 0.006c 9.61 (1.42–64.84) 0.020c
Silhouettes 1.24 (0.26–5.97) 0.793 0.98 (0.95–1.01) 0.976
Object Decision 1.50 (0.33–6.82) 0.600 0.91 (0.16–5.09) 0.916
Progressive Silhouettes 1.92 (0.27–13.63) 0.516 0.97 (0.10–9.30) 0.980
Dot Counting 4.41 (0.91–21.30) 0.065 3.18 (0.55–18.21) 0.195
Position Discrimination 10.86 (1.84–64.08) 0.008c 11.50 (1.37–96.24) 0.024c
Number Location 12.27 (1.35–111.61) 0.026c 10.85 (1.01–119.22) 0.050c
Cube Analysis 45.71 (2.39–874.17)d 0.0001c —e —e
Mattis DRS-2 (reverse-coded) mean total
score and mean subtest scores on outcome
of CBS-AD, with and without adjustment
for VOSP
Test mean used
Total 1.02 (0.99–1.06) 0.111 0.96 (0.90–1.01) 0.122
Attention 1.10 (0.98–1.23) 0.114 0.74 (0.55–0.99) 0.043
Initiation 1.03 (0.97–1.10) 0.335 0.88 (0.78–1.01) 0.066
Construction 1.28 (0.87–1.87) 0.211 0.77 (0.44–1.33) 0.340
Conceptualization 1.03 (0.90–1.19) 0.640 0.85 (0.67–1.07) 0.169
Memory 1.31 (1.08–1.58) 0.007c 1.17 (0.92–1.47) 0.205
Abbreviations: AD5 Alzheimer disease; CBS5 corticobasal syndrome; CI5 confidence interval; DRS-25Mattis Dementia
Rating Scale–2; OR 5 odds ratio; VOSP 5 Visual Object and Space Perception Battery.
ax2 or Fisher exact test.
b Logistic regression.
c Significant values.
dOne hundred percent of patients with CBS-AD failed this test, leading to an unpopulated cell. A value of 0.5 was thus
added to each cell to achieve an OR.
e Logistic regression invalid for binary predictor because of 100% failure of patients with CBS-AD. When a continuous
scale for Cube Analysis was adjusted with Mattis DRS-2 in logistic regression, the p value 5 0.009.
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secondary Lewy body pathology were removed from the
analysis (data not shown).
In multivariable analysis, the association between
VOSP subtest failure and CBS-AD was maintained
while adjusting for Mattis DRS-2 score (table 2),
and after independently adjusting for education, age
at visit, sex, and symptom laterality (data not shown).
Similar p values were obtained when adjusting for the
Mattis DRS-2 Attention subscale (data not shown).
Only Mattis DRS-2 Memory subscale was signifi-
cantly associated with CBS-AD, but this effect was abol-
ished when adjusting for total VOSP score. Furthermore,
failure on Incomplete Letters, Position Discrimination,
and Cube Analysis yielded much larger odds ratios
(ORs) for CBS-AD, and these remained significant while
adjusting for Mattis DRS-2 (table 2).
ROC curves for VOSP subtests and Mattis DRS-2
subtests. ROC curves were constructed to compare
area, sensitivity, and specificity for particular cutoff val-
ues on VOSP and Mattis DRS-2 subtests. Of the
VOSP subtests, area under the curve was significantly
greater than 50% for Incomplete Letters and all of
the dorsal stream subtests. Conversely, area under the
curve for Mattis DRS-2 Memory was significantly
greater than 50% while none of the other Mattis
DRS-2 subtests were significantly greater than
50% (table 3). The most favorable sensitivity and
specificity profiles were achieved for VOSP
Incomplete Letters and Cube Analysis. A visual
representation of VOSP Incomplete Letters and
Cube Analysis vs Mattis DRS-2 Memory and Mattis
DRS-2 Construction can be viewed in figure 2.
DISCUSSION We identified visuoperception dys-
function a priori in general as a predictor of underly-
ing AD pathology in CBS. Our secondary hypothesis
was that spatial perception in particular would be
affected. The present study demonstrated an associa-
tion between impaired performance on subtests of the
VOSP and an outcome of CBS-AD.
Both substreams of the dorsal (spatial) pathway end in
the parietal lobe. Given the preferential involvement of
parietal areas in CBS-AD as reported by previous au-
thors,4,5,12–14 we hypothesized that impaired performance
on spatial subtests would be associated with CBS-AD
when compared with CBS-nonAD. Indeed, among the
4 spatial subtests, 3 were associated with greater odds of
CBS-AD. The final spatial subtest, Dot Counting, had a
borderline-significant association. Furthermore, ROC
curves demonstrated statistical significance for all spatial
subtests, including Dot Counting, and appeared to dis-
tinguish CBS-AD from CBS-nonAD.
Among all VOSP subtests, failure on Cube Analysis
best distinguished CBS-AD. This test demonstrated the
Table 3 ROC curve area, cutoff values, sensitivity, and specificity of tests for CBS-AD
Area (accuracy) Area p value
Positive for AD if less
than or equal to Sensitivity, % Specificity, %
VOSP
Object subtests
Incomplete Letters 0.877 (0.758–0.996) 0.001a 18.5 90 69
Silhouettes 0.592 (0.384–0.801) 0.397 NA NA NA
Object Decision 0.660 (0.459–0.860) 0.143 NA NA NA
Progressive Silhouettes 0.502 (0.301–0.703) 0.986 NA NA NA
Spatial subtests
Dot Counting 0.794 (0.629–0.960) 0.007a 8.5 90 62
Position Discrimination 0.800 (0.654–0.946) 0.006a 17.5 80 69
Number Location 0.800 (0.655–0.945) 0.006a 6.00 90 58
Cube Analysis 0.913 (0.823–1.000) 0.0004a 4.50 100 77
Mattis DRS-2
Attention 0.712 (0.540–0.883) 0.052 NA NA NA
Initiation 0.596 (0.393–0.800) 0.377 NA NA NA
Construction 0.619 (0.425–0.813) 0.274 NA NA NA
Conceptualization 0.485 (0.244–0.725) 0.888 NA NA NA
Memory 0.815 (0.664–0.967) 0.004a 19.50 70 77
Abbreviations: AD 5 Alzheimer disease; CBS 5 corticobasal syndrome; DRS-2 5Mattis Dementia Rating Scale–2; NA 5 not applicable (the area under the
curve was not deemed to be significantly different than 50%); ROC 5 receiver operating characteristic; VOSP 5 Visual Object and Space Perception
Battery.
a Significant values.
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most favorable sensitivity and specificity combination
because of the 100% failure on this task among patients
with CBS-AD. The Cube Analysis task is the most chal-
lenging spatial subtest, even among healthy controls.22
This task differs from the other spatial tests because
although it is rendered as a 2-dimensional drawing, it
requires 3-dimensional perception. Furthermore, this
subtest entails identification of hidden cubes whose pres-
ence must be inferred.
Three-dimensional perception in nonhuman
primates is localized to the caudal intraparietal
area,23 and in humans, stereoscopic processing is
also seen in the parietooccipital junction.24
Impaired depth perception is also a feature of typ-
ical AD,25,26 and has been observed early in the dis-
ease course.27 The better discriminatory ability of the
Cube Analysis test for CBS-AD may reflect particularly
poor depth perception or impaired 3-dimensional
perception. A recent study on logopenic progressive
aphasia found that impaired performance on the Cube
Analysis task was associated with reduced gray matter
volume in bilateral parietal and occipital regions.28 Fur-
ther neuroimaging studies are necessary to relate per-
formance on this test with structural and functional
neuroanatomy.
Age is an important factor in tests of dorsal stream
function because spatial perception diminishes with
age; our data are consistent with other studies that
have revealed earlier age at onset for CBS-AD com-
pared with other pathologies.5,11,13 The relatively
young age of the patients with CBS-AD in this cohort
would likely bias our result toward the null (if increas-
ing age were causing an undetected spatial perfor-
mance decline on the dorsal stream subtests).
Furthermore, age-adjusted ORs were still significant
for each spatial subtest.
CBS-AD is thought to represent a form of early-
onset AD, but, at present, no genes have been iden-
tified11 (in our cohort, APOE e4 status did not
statistically differ between groups; nonetheless, the
only 2 e4 homozygotes did belong to the CBS-AD
group). Insofar as CBS-AD may represent a form of
early-onset AD, it is consistent that one study found
greater impairment of the dorsal stream in early-
onset AD than in late-onset AD.29
The relatively impaired performance on the spatial
subtests in CBS-AD was not likely due to worse gen-
eralized cognition, despite the trend toward worse
total Mattis DRS-2 score for the CBS-AD group
compared with CBS-nonAD. Dementia severity is
correlated with worse performance on neuropsycho-
logical tests, and other studies have demonstrated that
patients with CBS-AD may be more cognitively
impaired than patients with other pathologies.11
Thus, we adjusted for total Mattis DRS-2 score in
our analyses and the ORs remained significant. Given
the involvement of the right hemisphere in spatial
tasks, we also assessed the effect of disease laterality
on our findings, and found that hemispheric asym-
metry did not alter the result. Other potential con-
founders, such as education and sex, were not
significantly different between groups but were none-
theless individually adjusted for in multivariable anal-
yses. Finally, secondary diffuse Lewy body pathology,
which could conceivably account for visuoperceptual
Figure 2 ROC curves for subtests
Incomplete Letters andCubeAnalysis as comparedwithMattisMemory (A) andMattis Construc-
tion (B). Diagonal segments are produced by ties. ROC 5 receiver operating characteristic.
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dysfunction, did not appear to be driving the results
in the CBS-AD group.
The strong association of poor Incomplete Letters
performance with CBS-AD was unexpected, given
that the task is arguably the least challenging of the
subtests. This task requires identification of frag-
mented letters, and subjects may have had difficulty
mentally filling in the missing elements. This poor
perceptual closure capacity would represent a visual-
form, or apperceptive, visual agnosia, a disorder that
is theoretically measured by all of the object (or ven-
tral stream) subtests. Tasks involving incomplete
visual stimuli, such as Incomplete Letters, are the least
sensitive to visual organization difficulty, except in
relatively severe impairment.22
The CBS-AD group scored significantly lower on
the orientation-memory subtest of the Mattis DRS-2
in primary and secondary analyses. Of note, patients
with CBS-AD also perform worse on the orientation-
memory subcomponent of the Addenbrooke’s Cog-
nitive Examination,9 and a recent review of 42 CBS
cases identified memory impairment as being associ-
ated with CBS-AD11 (although the nature of this
impairment was not precisely defined). It remains
difficult to determine which aspect of memory may
be impaired because of the inclusion of orientation in
this scale. The Mattis DRS-2 Memory subcompo-
nent also includes verbal recall, verbal forced-choice
recognition memory, and visual forced-choice recog-
nition memory. Future studies should assess specific
types of memory in isolation.
Of note, the association of VOSP subtests with
CBS-AD was stronger than the association of Mattis
DRS-2 Memory and CBS-AD, as measured by ORs.
Furthermore, while VOSP subtest associations re-
mained significant after adjustment for Mattis DRS-
2 total score, the reverse was not true (Mattis DRS-2
Memory subscale adjusted for total VOSP score was
no longer significantly associated with CBS-AD).
Visual memory, assessed using the WMS-III, did
not differ among groups in primary and secondary
analysis. This is consistent with another CBS autopsy
study, which used the WMS-III.13 In a recent report,
visual memory, assessed by visuoconstruction of the
Rey Complex Figure, was impaired in CBS-AD.5 The
disparity between WMS-III and Rey Copy results
may be attributable to the fact that the WMS-III
relies on memory for faces, which may be localized
to more extensive brain regions.30 Despite this, we did
observe a trend toward worse performance by the
CBS-AD group on the WMS-III, especially on de-
layed visual recall.
Strengths of this study include its hypothesis-
driven design and the separation of visuoperception
from visuoconstruction and visual memory. Another
merit is the use of a test that minimizes the
importance of language and motor ability, and is
therefore clinically appropriate to CBS, where these
domains are impaired. One limitation is that we did
not formally assess for primary ocular pathology in
our subjects, particularly glaucoma, which is thought
to contribute to visual impairment in classic AD.31
However, the subjects in our CBS-AD group were
relatively young, and the prevalence of glaucoma in
those younger than 75 years has been estimated to be
only 0.9%.32 Furthermore, the VOSP requires sub-
jects to pass a screening test, which establishes acuity.
Another limitation is generic to autopsy studies:
because our sample contains only those 39 of 98
patients who came to autopsy during the study
period, the sample may be biased toward a shorter,
more aggressive course, resulting in the overrepresen-
tation of certain types of pathology. Therefore, we
calculated only ORs, sensitivity, and specificity
because of the possibility of this study misrepresent-
ing population prevalence of CBS-AD. Finally, the
external validity of this study may be limited, because
subjects were recruited to a tertiary academic medical
center.
We showed that pathologically confirmed CBS-AD
compared with CBS-nonAD is associated with poor
performance on the Incomplete Letters, Position
Discrimination, Number Location, and Cube Analy-
sis subtests of the VOSP. All VOSP spatial subtests
and the Incomplete Letters subtest showed accept-
able sensitivity for CBS-AD, and significantly ele-
vated ORs for CBS-AD. The sensitivity, specificity,
and ORs for these VOSP subtests exceeded those
of other neuropsychological measures, including tests
of memory.
Because of the pathologically heterogeneous
nature of CBS, diagnostic tools that predict under-
lying pathology are required, especially as etiology-
specific treatments become available. This study
shows that patterns of visuoperceptual impairment
in CBS may be linked to underlying AD pathol-
ogy, and this may benefit more accurate diagnosis,
classification, and treatment of this disease. The
VOSP is an inexpensive clinical tool that is quick
and easy to administer, and individual subtests
can be used in isolation. Incomplete Letters and
Cube Analysis may be particularly helpful in diag-
nosing underlying AD in patients presenting with
CBS.
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